



6 July 2026

## **CDC Independent Valuation – 30 June 2026**

CDC's independent valuation increased by 23.6% during the quarter to a mid-point of A\$18.5 billion. The increase was driven by strong growth in CDC's contracted capacity to more than 1GW, the acceleration of CDC's build programme to support this demand, and the expansion of CDC's total pipeline to FY40 from 2.6GW to 3.9GW of leasable capacity<sup>1</sup> to support future growth.

The 30 June 2026 independent valuation of CDC increased by A\$3.5 billion from 31 March 2026 to A\$18.5 billion, reflecting the mid-point of the assessed valuation range of A\$17.5 billion to A\$19.7 billion.

On this basis, the independent valuation of Infratil's 49.72% interest in CDC is A\$9,213 million, up A\$1,759 million from A\$7,454 million at 31 March 2026.

Further valuation details are included in the attached presentation document.

- (1) Pipeline and capacity disclosures have been updated to reflect leasable capacity, whereas previous disclosures were reported on a built capacity basis. The period for disclosure has also been extended from FY34 to FY40.

### **Enquiries should be directed to:**

Brett Jackson  
Investor Relations  
Email: [brett.jackson@infratil.com](mailto:brett.jackson@infratil.com)

### **Authorised for release by:**

Matthew Ross  
Infratil Chief Financial Officer